Isomorphic Labs, an AI drug development company led by Demis Hassabis, co-founder of Alphabet, has recently announced a $2.1 billion Series B funding round. The round was led by Thrive Capital, with participation from Alphabet and multiple sovereign wealth funds, aiming to advance AI-discovered candidate drugs into clinical trials.

The company, founded in 2021 and based in London, is dedicated to redefining the drug discovery process using artificial intelligence. This investment not only sets a new record in the field but also demonstrates the capital market's strong confidence in AI's potential to solve major human health challenges.

Building the IsoDDE Smart Platform

The funding will focus on expanding the company's internal AI development platform, IsoDDE, and further growing its global talent team. The platform integrates various proprietary AI models that can work across different therapeutic areas and drug categories, significantly shortening the early stages of drug development.

Hassabis stated that the company's underlying R&D approach has been validated, and the current task is to scale the technology. Combining reliable research data with efficient AI algorithms is gradually turning the ambitious mission of "solving all diseases" from a vision into reality.

Deepening Partnerships with Pharmaceutical Giants

Isomorphic Labs has established deep partnerships with global top pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson. Through sharing technology platforms and R&D pipelines, these industry leaders are leveraging AI to break through the traditional drug development bottleneck of "high investment, low output."

Industry experts believe that this funding marks a critical phase for AI-driven drug research entering clinical validation. As more AI-driven drugs enter clinical testing, the healthcare industry is expected to experience an efficiency revolution driven by computing power, offering more hope for patients around the world.